Quarterly report pursuant to Section 13 or 15(d)


3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Warrants 9. Warrants
Subsequent Accounting for Warrant Liabilities
Derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration and are included in derivative liabilities on the unaudited condensed consolidated balance sheets. Any change in fair value between the respective reporting dates is recognized as an unrealized gain or loss in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss (Note 15).
The following table is a summary of the number of shares of the Company’s Class A common stock issuable upon exercise of warrants at March 31, 2022:
Number of Shares
(in thousands)
Exercise Price Redemption Price Expiration Date Classification Gain (loss) in value for the three months ended March 31, 2022 (in thousands) Fair Value at March 31, 2022 (in thousands)
Public Warrants 15,813  $ 11.50  $ 18.00  9/9/2026 Liability $ 4,269  $ 4,428 
Private Placement Warrants 4,163  $ 11.50  $ 18.00  9/9/2026 Liability 1,166  1,332 
Private Placement Warrants 4,163  $ 20.00  $ 18.00  9/9/2026 Liability 250  749 
In addition, the Company has 1.8 million Class A common stock warrants outstanding which have an exercise price of $0.11 and expiration dates from June 27, 2028 to October 31, 2029. These warrants are equity classified and are included in additional paid-in capital in the Company’s unaudited condensed consolidated balance sheets.